HTL-STREFA, Inc.
HTL-STREFA, Inc. is the North American subsidiary of MTD Group, a global medtech manufacturer of diabetes care pen needles, safety lancets, syringes, and blood glucose monitoring systems, distributed across 100+ countries with combined capacity exceeding 2.5 billion pen needles annually.
- Company typePrivate
- Founded1995
- HeadquartersMarietta, United States
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What HTL-STREFA, Inc. does
HTL-STREFA, Inc. is the North American operating subsidiary of MTD Group (Medical Technology and Devices), a global medtech company formed in 2018 through the merger of Pikdare and HTL-Strefa. Headquartered in Marietta, Georgia (with the broader MTD Group headquartered in Milan, Italy), HTL-STREFA manufactures and distributes medical devices for diabetes care and drug delivery, including pen needles, safety lancets, syringes, blood glucose monitoring systems, and passive safety needles for healthcare professionals. The company serves diabetes patients and caregivers, healthcare professionals, and global pharmaceutical companies, operating in over 100 countries through direct sales forces in five key markets (Italy, France, Germany, North America, and India) complemented by an international distributor network that reaches nearly half the global population.
The company's technology portfolio centers on proprietary pen needle innovations—6-bevel needle design, click-on attachment mechanism, and double protection safety features—plus the world's thinnest 34G pen needle, Low Dead Space (LDS) syringes developed during COVID-19 to minimize vaccine waste, and a passive safety needle with auto-locking transparent shield. Four European production facilities spanning 135,500 m² deliver combined capacity exceeding 2.5 billion pen needles and approximately 5 billion medical devices annually. The portfolio is sold under sub-brands including Droplet (pen needles and insulin syringes with 50% global share in safety lancets and 15% share in personal lancets), Dropsafe (healthcare worker safety solutions), and mylife (Swiss-designed blood glucose monitoring systems and pen needles). HTL-STREFA is #2 globally and the fastest-growing pen needle brand in North America under Droplet.
HTL-STREFA's business model is hardware-based sales of Class II medical devices through a hybrid channel mix: direct enterprise sales to pharmaceutical companies for drug delivery contract manufacturing, retail chain partnerships (notably in North America for the diabetes segment), dominant pharmacy channel positioning in France, and distributor-led coverage in 100+ additional countries. Pricing is not publicly disclosed and operates on a B2B quote basis. The company holds ISO 13485:2016, FDA 510(k), and ISO 14001 certifications, with a portfolio of 300+ registered patents. HTL-STREFA is a wholly-owned subsidiary of MTD Group, which is majority owned by private equity sponsors Investindustrial and QuattroR SGR.
HTL-STREFA, Inc. firmographics
Firmographics- Name
- HTL-STREFA, Inc.
- Legal name
- HTL-Strefa Inc.
- Website
- http://www.htl-strefa.com
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Short description
- HTL-STREFA, Inc. is the North American subsidiary of MTD Group, a global medtech manufacturer of diabetes care pen needles, safety lancets, syringes, and blood glucose monitoring systems, distributed across 100+ countries with combined capacity exceeding 2.5 billion pen needles annually.
- Ownership category
- akta.pro rank
HTL-STREFA, Inc. industry classification
Industry- Product category
- Diabetes Care Medical Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Wholesale-Medical, Dental & Hospital Equipment & Supplies (5047), In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE)
- akta.pro secondary industries
- Blood Glucose Monitoring (BGM) Meters & Test Strips (HLAHAHAG), Personal Protective Equipment (PPE) (Gloves, Masks/Respirators, Gowns, Face Shields) (HLAHANAF)
Keywords
Where HTL-STREFA, Inc. is headquartered
LocationHeadquarters
- HQ city
- Marietta
- HQ country
- United States
- HQ region
- North America
Offices7 records
Markets served
HTL-STREFA, Inc. business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Medical Device Sales: Sale of medical devices including pen needles, safety lancets, syringes, blood glucose monitors, and other diabetes care products through direct sales, distributors, and retail partnerships
Go-to-market motion1 record
Distribution channels5 records
Marketing channels4 records
HTL-STREFA, Inc. product offering
Product offeringCore offering
HTL-STREFA, Inc. manufactures and distributes medical devices for diabetes care, blood glucose monitoring, and drug delivery. Its core products are safety lancets for capillary blood sampling, disposable pen needles for insulin injection (including the world's thinnest 34G needle under the Droplet brand), insulin syringes, and blood glucose monitoring systems (mylife brand). The company also offers safety medical devices for healthcare professionals such as the Dropsafe passive safety needle. HTL-STREFA serves hospitals, clinics, laboratories, retail pharmacies, and home users globally, shipping nearly 10 million products daily from its Polish production facilities.
Product overview
MTD Group operates as a med-tech company encompassing HTL-STREFA, Pikdare, and multiple sub-brands including Droplet, Dropsafe, and mylife. The portfolio centers on diabetes care products—pen needles (the world's thinnest and shortest 34G), safety lancets, and blood glucose monitoring systems—alongside safety devices for healthcare professionals (passive safety needles, safety lancets), and home-use medical devices (glucometers, thermometers, nebulizers). HTL-STREFA specifically manufactures and distributes safety lancets and pen needles for hospitals, clinics, laboratories, and home use, shipping nearly 10 million products daily from facilities in Poland.
Differentiator
Problem solved
Functional benefit
Brands
- Droplet: A brand specifically for diabetes, recognized worldwide for reliability and safety. Known for pen needles and insulin syringes, and is the fastest-growing pen needle brand in North America with 15% market share for personal lancets.
- Dropsafe
- mylife
Products and services
- Pen Needles (Droplet, mylife, HTL-STREFA brands)
- Safety Lancets (Droplet and HTL-STREFA brands)
- mylife Blood Glucose Monitoring Systems
- Dropsafe Passive Safety Needle
- 31G Safety Pen Needle
- Low Dead Space (LDS) Syringes
- TRUEplus 5-Bevel Pen Needles
- Droplet Insulin Syringes
Quantifiable outcome
- 98.18% successful injection completion rate with passive safety needle in clinical studies
- +4 more outcomes
Companies that use HTL-STREFA, Inc.
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles4 records
HTL-STREFA, Inc. technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature7 records
HTL-STREFA, Inc. partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered minor and core.
- Theras GroupminorMTD sold Pic Solution consumer healthcare brand to Theras Group while retaining manufacturing partnership to supply pen needles. Products continue to be produced at MTD's Italian facility under one of Italy's most established self-care brands.
- Ypsomed Holding AGcoreMTD acquired Ypsomed's pen needle and blood glucose monitoring businesses in March 2024, integrating their 6-bevel and click technologies into MTD's product portfolio. The acquisition strengthens MTD's position as global #2 pen needle manufacturer with combined capacity exceeding 2.5 billion units.
Scale indicators12 records
Recent moves6 records
Expansion highlights6 records
HTL-STREFA, Inc. competitors and assessment
Company assessmentBroad incumbents
- Becton, Dickinson and Company (BD): BD is one of the largest global manufacturers of syringes, pen needles, safety lancets, and injection systems, serving hospitals, retail pharmacies, and pharma partners. It is a broad incumbent with overlapping product categories in diabetes delivery consumables.
- Terumo Corporation: Terumo is a major manufacturer of syringes, pen needles, lancets, and broader medical devices. It competes directly with MTD/HTL-STREFA in pen needles and syringes for diabetes and pharmaceutical applications.
Direct peers
- Owen Mumford: Owen Mumford manufactures pen needles, safety lancets, and auto-injectors for diabetes care and self-medication, with strong global distribution. It is a direct peer to HTL-STREFA in pen needles and safety lancets.
- Nipro Corporation: Nipro manufactures pen needles, syringes, lancets, and diabetes-related devices globally. It is a direct peer in injection and blood sampling consumables serving the same diabetes and pharma customers.
- Smiths Medical (ICU Medical): Smiths Medical, now part of ICU Medical, produces syringes, safety needles, and infusion devices for hospitals and home care. It is a direct peer in safety needle and syringe product categories.
- ARKRAY, Inc. ARKRAY is a Japanese manufacturer specializing in blood glucose monitoring systems, lancets, and diabetes diagnostic consumables. It is a direct peer in BGM devices and personal lancets.
- Ascensia Diabetes Care: Ascensia Diabetes Care produces CONTOUR blood glucose monitoring systems and consumables globally. It is a direct peer in BGM devices following MTD's acquisition of Ypsomed's BGM business.
- Allison Medical, Inc. Allison Medical manufactures safety lancets, pen needles, and diabetes care accessories, and is a long-standing competitor in the US lancet and pen needle market. It is a direct peer in disposable diabetes consumables.
Emerging players
- Gerresheimer AG: Gerresheimer produces primary packaging, syringes, and drug delivery devices for pharmaceutical and diabetes applications. It overlaps with MTD/HTL-STREFA in prefillable syringes and drug delivery solutions.
Others
- Ypsomed Holding AG: Post-divestiture of its pen needle and BGM businesses to MTD in 2024, Ypsomed now focuses on injection systems and auto-injectors for pharma. It is an adjacent player whose prior pen needle portfolio is now integrated into MTD/HTL-STREFA.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
HTL-STREFA, Inc. social profiles
Digital presenceHTL-STREFA, Inc. compliance and trust
Trust signalCompliance5 records
HTL-STREFA, Inc. financial estimates
Financial estimateRevenue estimate
Valuation estimate
HTL-STREFA, Inc. leadership team
Management profileNumber of profiles
Profiles2 records
HTL-STREFA, Inc. funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
HTL-STREFA, Inc. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about HTL-STREFA, Inc.
What does HTL-STREFA, Inc. do?
HTL-STREFA, Inc. manufactures and distributes medical devices for diabetes care, blood glucose monitoring, and drug delivery. Its core products are safety lancets for capillary blood sampling, disposable pen needles for insulin injection (including the world's thinnest 34G needle under the Droplet brand), insulin syringes, and blood glucose monitoring systems (mylife brand). The company also offers safety medical devices for healthcare professionals such as the Dropsafe passive safety needle. HTL-STREFA serves hospitals, clinics, laboratories, retail pharmacies, and home users globally, shipping nearly 10 million products daily from its Polish production facilities.
Is HTL-STREFA, Inc. a public or private company?
HTL-STREFA, Inc. is a private company. It is classified as private equity controlled and is currently operating.
When was HTL-STREFA, Inc. founded?
HTL-STREFA, Inc. was founded in 1995. It employs 501 to 1,000 people.
Where is HTL-STREFA, Inc. based?
HTL-STREFA, Inc. is headquartered in Marietta, United States, in the North America region.
How does HTL-STREFA, Inc. make money?
One revenue line is on record: medical Device Sales.
Who are HTL-STREFA, Inc.'s main competitors?
Broad incumbents on record are Becton, Dickinson and Company (BD) and Terumo Corporation. Direct peers are Owen Mumford, Nipro Corporation, Smiths Medical (ICU Medical), ARKRAY, Inc., Ascensia Diabetes Care and Allison Medical, Inc.. Gerresheimer AG is listed as an emerging player. Ypsomed Holding AG is listed as an others.
Does HTL-STREFA, Inc. have an API?
No public API is recorded for HTL-STREFA, Inc..
What industry is HTL-STREFA, Inc. in?
HTL-STREFA, Inc.'s product category is Diabetes Care Medical Devices. Its primary akta.pro industry code is HLAHAHAE, Insulin Pen Needles, Syringes & Infusion Sets (Consumables), with a secondary code of HLAHAHAG, Blood Glucose Monitoring (BGM) Meters & Test Strips. Its NAICS code is 339112 and its SIC code is 3841.